Geneva, Switzerland (PRWEB) April 17, 2013
Selexis SA, a serial innovation company focused on drug discovery for lead identification, cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the launch of its novel platform, SURE CHO-Mplus™ Libraries, which were designed and constructed to address a broad range of issues surrounding recombinant protein secretion including metabolic limitations, trafficking backlogs, improper folding and altered post-translational modifications.
With certain recombinant proteins, optimal expression cannot be achieved by elevated transcription alone. Low productivity can be the result of a myriad of issues including faulty cleavage and protein precipitation, improper folding, metabolic overload, or backlog in protein translocation or vesicle trafficking. Within each of the Company’s SURE CHO-Mplus™ Libraries, between 8-12 secretory components have been modified to address specific secretion bottlenecks, such as aberrant glycosylation or improper protein folding. The SURE CHO-Mplus™ Libraries have been shown to significantly improve production levels of a broad range of proteins including difficult-to-express monoclonal antibodies, enzymes, structural proteins and fusion proteins such as Fc-fusions and minibodies.
“The Selexis SURE CHO-Mplus™ Libraries are a novel and powerful advancement in biologic protein expression. Selexis’ libraries enable a multiplex approach to determine optimal secretory configurations for recombinant proteins,” said Dr. Igor Fisch, CEO, Selexis SA. “With the Selexis SURE CHO-Mplus™ Libraries, biopharmaceutical companies now have solutions for optimizing the commercial viability of biologic development programs including target expression campaigns that would be otherwise terminated because of protein secretion issues.”
The CHO-Mplus™ Libraries that address secretion bottlenecks include:
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information:
Read the full story at http://www.prweb.com/releases/secretion_bottlenecks/recombinant_proteins/prweb10639998.htm.
Copyright©2012 Vocus, Inc.
All rights reserved